SalubRx Therapeutics Inc. is a privately owned semi-virtual pharmaceutical company developing new chemical entities (NCEs) for the treatment of neurological disorders.
SalubRx Therapeutics Inc. has developed a platform of selective inhibitors of the nitric oxide synthase (NOS) enzyme family, the enzyme which produces nitric oxide (NO).
As the first company to be able to specifically target and inhibit the individual isozymes (nNOS, eNOS, iNOS), SalubRx Therapeutics Inc. can avoid any of the effects of blood pressure usually associated with eNOS providing the benefits of nNOS and iNOS alone or in combination as required.
NO has been implicated in a wide variety of neurological disorders from migraine through to neurodegeneration. SalubRx Therapeutics Inc.’s selective NOS inhibitors may be especially suited to neurodegenerative diseases as a transformative symptomatic and disease modifying treatment. Parkinson’s Disease (PD) in particular may be particularly amenable to NOS based therapeutics.
SalubRx Therapeutics Inc. has developed the NOS technology under an exclusive license from Knight Therapeutics.
SalubRx Therapeutics Inc. is a privately owned semi-virtual pharmaceutical company developing new chemical entities (NCEs) for the treatment of neurological disorders..Read more
SalubRx Therapeutics Inc.has a pipeline of clinical and preclinical New Chemical Entities (NCEs) as clinical leads, back-ups and new developments.Read more